当前位置: X-MOL 学术Eur. J. Heart Fail. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
European Journal of Heart Failure ( IF 18.2 ) Pub Date : 2021-11-20 , DOI: 10.1002/ejhf.2386
Javed Butler 1 , Stefan D Anker 2 , Tariq Jamal Siddiqi 3 , Andrew J S Coats 4 , Fabio Dorigotti 5 , Gerasimos Filippatos 6 , Tim Friede 7, 8 , Udo-Michael Göhring 5 , Mikhail N Kosiborod 9 , Lars H Lund 10 , Marco Metra 11 , Carol Moreno Quinn 5 , Ileana L Piña 12 , Fausto J Pinto 13 , Patrick Rossignol 14 , Peter Szecsödy 5 , Peter Van Der Meer 15 , Matthew Weir 16 , Bertram Pitt 17
Affiliation  

In patients with current or a history of hyperkalaemia, treatment with renin–angiotensin–aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+) binder, may improve serum K+ levels and adherence to RAASi.

中文翻译:

Patiromer 用于治疗接受肾素-血管紧张素-醛固酮系统抑制剂治疗心力衰竭的患者的高钾血症:DIAMOND 试验的设计和基本原理

在目前或有高钾血症病史的患者中,肾素-血管紧张素-醛固酮系统抑制剂 (RAASi) 的治疗通常会受到影响。Patiromer 是一种新型钾 (K + ) 粘合剂,可改善血清 K +水平和对 RAASi 的依从性。
更新日期:2022-01-28
down
wechat
bug